Eptinezumab Demonstrates Early Relief from Episodic and Chronic Migraine: Consistency of Effect Across 4 Clinical Trials

被引：0
|
作者：
Dodick, David [1 ]
Smith, Timothy [2 ]
Cady, Roger [3 ]
Schaeffler, Barbara [3 ]
Smith, Jeff [4 ]
Biondi, David [3 ]
Hirman, Joe [5 ]
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Study Metrix Res LLC, St Peters, MO USA
[3] Alder BioPharmaceut Inc, Bothell, WA USA
[4] Alder BioPharmaceut Ltd, Dublin, Ireland
[5] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
来源：
NEUROLOGY | 2019年 / 92卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S17.004
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Early Impact of Eptinezumab on the Health-Related Quality of Life (HRQoL) of Patients with Episodic or Chronic Migraine: SF-36 Analysis Across the Spectrum of Migraine
    Diamond, Merle
    Lipton, Richard
    Horblyuk, Ruslan
    Hirman, Joe
    Cady, Roger
    Kassel, Eric
    NEUROLOGY, 2019, 92 (15)
  • [2] Eptinezumab Reduces the Frequency of Headaches and Migraines in Patients with Episodic or Chronic Migraine: Results from the PROMISE 1 and PROMISE 2 Trials
    Mechtler, L. L.
    Schim, J.
    Kassel, E.
    Cady, R.
    Hirman, J.
    HEADACHE, 2019, 59 : 34 - 34
  • [3] Migraine-Free Months in Patients with Episodic or Chronic Migraine Treated with Eptinezumab: Results from the PROMISE-1 and PROMISE-2 Trials
    Winner, P. K.
    McAllister, P.
    Cady, R.
    Snapinn, S.
    Hirman, J.
    Kassel, E.
    HEADACHE, 2019, 59 : 162 - 162
  • [4] A clinical comparison demonstrates similarities between chronic and high frequency episodic migraine
    Pozo-Rosich, P.
    Quintana, M.
    Torres, M.
    Fernandez-Morales, J.
    Alvarez-Sabin, J.
    JOURNAL OF HEADACHE AND PAIN, 2014, 15
  • [5] Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
    Day, Kathleen A.
    Ament, Michael
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Zhang, Qi
    Pearlman, Eric M.
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [6] EHMTI-0288. A clinical comparison demonstrates similarities between chronic and high frequency episodic migraine
    P Pozo-Rosich
    M Quintana
    M Torres
    J Fernandez-Morales
    J Alvarez-Sabin
    The Journal of Headache and Pain, 2014, 15
  • [7] Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
    Michael Ament
    Kathleen Day
    Virginia L. Stauffer
    Vladimir Skljarevski
    Mallikarjuna Rettiganti
    Eric Pearlman
    Sheena K. Aurora
    The Journal of Headache and Pain, 2021, 22
  • [8] Effect of Galcanezumab on Severity of Headache and Associated Symptoms of Migraine in Phase 3 Trials in Patients with Episodic or Chronic Migraine
    Day, Kathleen A.
    Ament, Michael
    Stauffer, Virginia L.
    Skljarevski, Vladimir
    Rettiganti, Mallikarjuna
    Pearlman, Eric M.
    Aurora, Sheena K.
    NEUROLOGY, 2019, 92 (15)
  • [9] IMPACT OF EPTINEZUMAB ON THE HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS WITH EPISODIC OR CHRONIC MIGRAINE: SF-36 ANALYSIS BY MONTHS 1 AND 3 ACROSS THE SPECTRUM OF MIGRAINE
    Diamond, M.
    Lipton, R. B.
    Horblyuk, R.
    Hirman, J.
    Cady, R.
    Kassel, E.
    VALUE IN HEALTH, 2019, 22 : S285 - S285
  • [10] Immunogenicity findings from Phase 3 galcanezumab trials in patients with episodic or chronic migraine
    Martinez, James M.
    Garce, Sandra
    Anglin, Greg
    Hodsdon, Michael
    Kielbasa, William
    Moser, Brian A.
    Pearlman, Eric
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
12345